HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PGEN
Precigen, Inc.
There isn't enough reported data to score PGEN yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PGEN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Unavailable |
PGEN's profitability is currently healthy. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PGEN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 7.2x | $4.66 | — |
| Cheap | 7.9x | $0.55 | -88% |
| Fair | 9.5x | $0.66 | -86% |
| Expensive | 14x | $0.98 | -79% |
| Current | 67x | $4.66 | — |
Historical ranges are pointers, not guarantees.
PGEN's PE is 67x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PGEN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
PGEN has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.65 | +829% |
| Q3 2026 | $0.07 | +$1.45 |
| Q2 2026 | -$1.07 | -$0.66 |
| Q1 2026 | -$1.21 | -$0.66 |
| Q4 2025 | -$1.37 | -$0.90 |
| Q3 2025 | -$1.38 | -$0.83 |
| Q2 2025 | -$0.41 | +$0.13 |
| Q1 2025 | -$0.55 | -$0.16 |
| Q4 2024 | -$0.47 | -$0.08 |
PGEN has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
PGEN has the stronger quarterly revenue trend. Revenue is up 49% for HIMS versus up 3,906% for PGEN.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2023 | $1.8M | -39% |
| Q1 2023 | $1.9M | -94% |
| Q4 2022 | $1.8M | -93% |
| Q3 2022 | $16.7M | -22% |
| Q2 2022 | $2.9M | -91% |
| Q1 2022 | $32M | +31% |
| Q4 2021 | $24.2M | +25% |
| Q3 2021 | $21.6M | -8.6% |
PGEN's revenue is growing: $74M last quarter, up 3906% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 52% | N/A |
| Q2 2026 | 41% | N/A |
| Q1 2026 | -26% | N/A |
| Q2 2023 | -1154% | -255 points |
| Q1 2023 | -1231% | -1171 points |
| Q4 2022 | -1257% | -1154 points |
| Q3 2022 | -46% | +93 points |
| Q2 2022 | -898% | -838 points |
PGEN has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PGEN on cash generation, producing positive trailing cash flow while its opponent burns cash.
PGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $11.4M | +$40.9M |
| Q2 2026 | -$18.2M | +$1.7M |
| Q1 2026 | -$44.1M | -$27.1M |
| Q4 2025 | -$23.5M | -$14.2M |
| Q3 2025 | -$29.5M | -$5.8M |
| Q2 2025 | -$19.9M | +$5.5M |
| Q1 2025 | -$16.9M | +$1.5M |
| Q4 2024 | -$9.3M | +$7.5M |
PGEN has burned cash in almost every quarter: −$74M over the past year, against −$76M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PGEN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.8% | +7.5M shares |
| 1 year | +37% | +114M shares |
| 3 years | +69% | +173M shares |
| 5 years | +112% | +222M shares |
| Available history | +173% | +267M shares |
PGEN has 421M diluted shares, up 37% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PGEN Net Leverage
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.6 | Neutral |
| Stochastic | 23.8 | Neutral |
PGEN's weekly RSI is 43 (neutral) and its Stochastic is 24 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PGEN PE vs Healthcare Sector
| Metric | PGEN | Sector median | Relative |
|---|---|---|---|
| PE | 67x | 26x | 158% above |
| PE % | 100 | 29 | 71 pts above |
PGEN is trading at 67x earnings, a 158% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.59 | 29% below |
| 20 week MA | $6.48 | 28% below |
| 50 week MA | $5.10 | 8.6% below |
| 100 week MA | $3.68 | 27% above |
| 200 week MA | $2.48 | 88% above |
PGEN has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.74 | $10.0 | +75% |
| 2021 | $10.0 | $4.10 | -59% |
| 2022 | $4.10 | $1.40 | -66% |
| 2023 | $1.40 | $1.34 | -4.3% |
| 2024 | $1.34 | $0.73 | -46% |
| 2025 | $0.73 | $4.16 | +470% |
| 2026 YTD | $4.16 | $4.66 | +12% |
PGEN has the edge over HIMS on returns for 2026, with the stronger performance.